TrialInternational journal of hematology2009

Lenalidomide is active in Japanese patients with symptomatic anemia in low- or intermediate-1 risk myelodysplastic syndromes with a deletion 5q abnormality.

Hironori Harada et al.PubMed ↗Publisher ↗

No numbers read from the abstract.